U.S. House panel to hold May 18 hearing over AbbVie drug pricing

This post was originally published on this site

The hearing with CEO Richard Gonzalez will examine prices for Humira, which have been hiked 27 times, and Imbruvica, which saw prices rise nine times, the House Committee on Oversight and Reform Committee said in a statement.